Related Experiment Video
Updated: May 8, 2025
Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses
Published on: January 20, 2017
Azvudine efficacy in reducing mortality in COVID-19 patients
Zhen Zhong1, Xiao-Feng Liu1, Xiao-Zhong Zhou1
1Department of Emergency, First Affiliated Hospital of Gannan Medical University, 128 Jinling Road, Zhanggong District, Ganzhou City, Jiangxi Province, China.
Background:
Several therapeutic drugs have been authorized for the treatment of patients with Coronavirus disease 2019 (COVID-19). However, further research on the mechanisms of action, efficacy, and target populations of these novel therapeutic drugs are necessary. This study included mild, moderate, severe, and critical COVID-19 patients to evaluate azvudine's effectiveness across different severity levels.
Methods:
We conducted a retrospective cohort study of patients with COVID-19 admitted to our hospital from December 1, 2022, to March 31, 2023. Patients were divided into retrospective cohorts receiving azvudine antiviral therapy and standard treatment, and were followed-up for up to 28 days.
Results:
Prior to data processing, azvudine treatment was associated with reduced mortality rates at 7 days (1.09/1000 persons vs. 5.06/1000 persons, P < 0.001) and 14 days (3.35/1000 persons vs. 5.65/1000 persons, P = 0.001). After propensity score matching, a decrease in mortality rates at 7 days (0.8/1000 persons vs. 6.29/1000 persons, P < 0.001), 14 days (3.42/1000 persons vs. 7.26/1000 persons, P < 0.001), and 28 days (4.33/1000 persons vs. 7.29/1000 persons, P = 0.003) were observed following azvudine treatment. After inverse probability of treatment weighting adjustment, the results were consistent with propensity score matching. In the clinical subgroup analysis, azvudine treatment intervention significantly reduced the 7-day (2.49/1000 persons vs. 14.59/1000 persons, P = 0.001 and 11.36/1000 persons vs. 66.99/1000 persons, P < 0.001), 14-day (5.22/1000 persons vs. 17.36/1000 persons, P < 0.001 and 17.08/1000 persons vs. 51.72/1000 persons, P = 0.002), and 28-day (7.58/1000 persons vs. 16.02/1000 persons, P = 0.014 and 20.43/1000 persons vs. 46.51/1000 persons, P = 0.008) mortality rates in hospitalized patients with severe and critical COVID-19.
Conclusions:
The study suggests that in hospitalized patients with COVID-19, azvudine treatment significantly reduces patient mortality rates in hospitalized COVID-19 infections, wherein the effects are more pronounced in severe and critical patients.
Insights
Azvudine treatment significantly reduced mortality rates in hospitalized patients with Coronavirus disease 2019 (COVID-19). The antiviral drug showed more pronounced effects in severe and critical cases, improving survival outcomes.
Area of Science:
- Virology
- Infectious Diseases
- Pharmacology
Background:
- Several drugs are approved for Coronavirus disease 2019 (COVID-19) treatment.
- Further research is needed on novel therapeutic mechanisms, efficacy, and patient populations.
- This study evaluated azvudine effectiveness across mild, moderate, severe, and critical COVID-19 cases.
Purpose of the Study:
- To assess the effectiveness of azvudine in reducing mortality rates among hospitalized COVID-19 patients.
- To compare azvudine treatment outcomes with standard care.
- To analyze azvudine's impact across different COVID-19 severity levels.
Main Methods:
- Retrospective cohort study of COVID-19 patients from December 2022 to March 2023.
- Patients received either azvudine antiviral therapy or standard treatment.
- Follow-up for up to 28 days, with statistical adjustments using propensity score matching and inverse probability of treatment weighting.
Main Results:
- Azvudine treatment was associated with significantly reduced mortality rates at 7, 14, and 28 days post-admission.
- Propensity score matching and weighting adjustments confirmed these findings.
- Subgroup analysis showed a more pronounced mortality reduction in severe and critical COVID-19 patients.
Conclusions:
- Azvudine treatment significantly lowers mortality in hospitalized COVID-19 patients.
- The therapeutic benefits of azvudine are particularly evident in severe and critical cases.
- Azvudine represents a promising therapeutic option for managing severe COVID-19 infections.
Related Concept Videos
01:21Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
01:30Acute Respiratory Failure-III
01:23Acute Respiratory Failure-IV
01:21Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: